1. Localised and Locally Advanced Prostate Cancer: Who to Treat and How?
David Gillatt, Laurence Klotz, Colleen Lawton, Kurt Miller, Heather Payne 
European Urology Supplements 
Volume 6, Issue 3, Pages (March 2007)
DOI: /j.eursup
Copyright © 2006 European Association of Urology Terms and Conditions

2. Fig. 1
Clinical benefits of adding hormonal therapy to radical prostatectomy in patients with locally advanced disease. (A) Overall survival of Zoladex adjuvant to radical prostatectomy at 11.9 yr median follow-up (n=98) [28] (Reprinted from Messing EM, et al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 2006;7:472–9, copyright 2006 with permission from Elsevier Inc). (B) Objective progression-free survival of Casodex 150mg adjuvant to radical prostatectomy at 7.6 yr median follow-up (n=1719) [36].
European Urology Supplements 2007 6, DOI: ( /j.eursup )
Copyright © 2006 European Association of Urology Terms and Conditions

3. Fig. 2
In patients with locally advanced disease, the overall survival benefits observed with (A) Zoladex adjuvant to radiotherapy in RTOG at 7.6 yr median follow-up (n=977) [31] (Reprinted from Pilepich MV, et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma—long term results of phase III RTOG Int J Radiat Oncol Biol Phys 2005;61:1285–90, copyright 2005 with permission from Elsevier Inc) and (B) Casodex 150mg adjuvant to radiotherapy in EPC programme at 7.2 yr median follow-up (n=305) [35] (Reprinted with kind permission of Springer Science and Business Media) were driven by a lower number of prostate cancer deaths.
European Urology Supplements 2007 6, DOI: ( /j.eursup )
Copyright © 2006 European Association of Urology Terms and Conditions

4. Fig. 3
In patients with locally advanced disease, a significant overall survival benefit was observed with Casodex 150mg versus watchful waiting patients in the SPCG-6 study (also known as Trial 25 of the EPC programme) at 7.1 yr median follow-up (n=359) [34] (Reproduced with kind permission of Taylor & Francis).
European Urology Supplements 2007 6, DOI: ( /j.eursup )
Copyright © 2006 European Association of Urology Terms and Conditions